References
- Global Cancer Observatory: Cancer Today [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2022 Jul 24]. Available from: http://gco.iarc.fr/today/home.
- Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol. 1962;74:229–236.
- EMA. Fluorouracil/salicylic acid. Amsterdam: European Medicines Agency; 2018.
- Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7(1):45–63.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- Ottawa Hospital Research Institute [Internet]. Ottawa (Canada): Ottawa Hospital Research Institute; 2021 [cited 2022 Aug 3]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. GRADE system: classification of quality of evidence and strength of recommendation. Cir Esp. 2014;92(2):82–88.
- EMA. Nexavar [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar.
- Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006;31(6):783–785.
- EMA. Sutent [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sutent.
- Mir-Bonafé JM, Cañueto J, Bravo J, et al. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma. Int J Dermatol. 2013;52(11):1445–1447.
- EMA. Tarceva [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018. [cited 2022 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva.
- Hermanns JF, Piérard G, Quatresooz P. Erlotinib-responsive actinic keratoses. Oncol Rep. 2007;18(3):581–584.
- EMA. Taxotere [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Jul 29]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere.
- Kluger N, Rentola L, Hervonen P, et al. Inflammation of actinic keratoses after docetaxel. Presse Med. 2018;47(6):598–599.
- EMA. Abraxane [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Jul 29]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane.
- Ali FR, Yiu ZZN, Fitzgerald D. Inflammation of actinic keratoses during paclitaxel chemotherapy. BMJ Case Rep. 2015;2015(1):bcr2015209925.
- EMA. Alimta [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 2]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/alimta.
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis – international league of dermatological societies in cooperation with the european dermatology forum – short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–2079.
- EMA. Xeloda [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda.
- Lewis KG, Lewis MD, Robinson-Bostom L, et al. Inflammation of actinic keratoses during capecitabine therapy. Arch Dermatol. 2004;140(3):367–368.
- Stanciu M, Aubut N, Gagné E, et al. Capecitabine-Induced inflammation of actinic keratosis: case report and literature review. J Cutan Med Surg. 2012;16(5):298–299.
- Peramiquel L, Dalmau J, Puig L, et al. Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. J Am Acad Dermatol. 2006;55(5):S119–S120.
- Higa GM, Kovach RF, Abraham J. Actinic keratosis and capecitabine therapy. J Oncol Pharm Pract. 2005;11(4):151–153.
- Willey A, Glusac EJ, Bolognia JL. Photoeruption in a patient treated with capecitabine (xeloda) for metastatic breast cancer. J Am Acad Dermatol. 2002;47(3):453.
- Krathen M, Treat J, James WD. Capecitabine induced inflammation of actinic keratoses. Dermatol Online J. 2007;13(4):13.
- Serrão VV, Feio AB. Inflammation of actinic keratoses with capecitabine therapy for colon cancer. Eur J Dermatol. 2008;18(2):200.
- Al-Niaimi F, Lyon C. Resolving actinic keratoses: an expected side-effect of capecitabine therapy: correspondence. Clin Exp Dermatol. 2012;37(1):68–69.
- EMC. Fluorouracil 50 mg/ml injection - summary of product characteristics (SmPC) - (emc).. Surrey (UK): Datapharm; 2022.
- Torre D. Inflammation of actinic keratosis secondary to systemic 5-fluorouracil. Arch Dermatol. 1968;98(1):95–96.
- Bataille V, Cunningham D, Mansi J, et al. Inflammation of solar keratoses following systemic 5-fluorouracil. Br J Dermatol. 1996;135(3):478–480.
- Omura EF, Torre D. Inflammation of actinic keratoses due to systemic fluorouracil therapy. JAMA. 1969;208(1):150–151.
- Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol. 1987;17(2):192–197.
- EMA. Vectibix [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix.
- Escudero-Góngora MM, del Pozo-Hernando LJ, Corral-Magaña O, et al. Inflammation of actinic keratosis during panitumumab therapy. Actas Dermosifiliogr. 2018;109(8):749–751.
- EMA. Caelyx pegylated liposomal [Internet]. Amsterdam (The Netherlands): European Medicines Agency; 2018 [cited 2022 Aug 2]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal.
- EMC. Nipent 10 mg powder for solution for injection, powder for solution for infusion - summary of product characteristics (SmPC) - (emc). Surrey (UK): Datapharm; 2021.
- Camisa C, Grever MR, Bouroncle B. Deoxycoformycin: a new chemotherapeutic agent of interest to dermatologists. J Am Acad Dermatol. 1985;12(6):1108–1109.
- Lam J, Ellis SR, Sivamani RK. Inflamed actinic keratoses associated with pemetrexed and carboplatin therapy. Dermatol Online J. 2017;23(10):13030.
- Makdsi F, DeVersa R. Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. Cases J. 2009;2(1):6946.
- Chambers CJ, Liu H, White CR, et al. Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature. Dermatol Online J. 2014;20(1):21246.
- Ilyas EN, Grana G, Green JJ. Inflammatory actinic keratoses secondary to systemic chemotherapy. Cutis. 2005;75(3):167–168.
- Ghaferi J, Douglass M. Inflammation of actinic keratoses secondary to systemic chemothrapy. J Am Acad Dermatol. 2010;62(3):AB93.
- Kirkup ME, Narayan S, Kennedy CTC. Cutaneous recall reactions with systemic fluorouracil. Dermatology. 2003;206(2):175–176.
- Sollitto RB. An oncology patient with an erythematous papulosquamous eruption in sun-exposed areas. Arch Dermatol. 1994;130(9):1197.
- Bernstein T. Skin reactions to 5-fluorouracil. N Engl J Med. 1977;297(6):337–338.
- Garcia-Rodrigo GC, Sanz-Motilva V, Ortiz de Frutos J, et al. Pemetrexed-related cytotoxic skin reaction. J Am Acad Dermatol. 2015;72(5):AB211.
- Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. JAMA Dermatol. 2020;156(10):1117–1124.
- Goette DK. Topical chemotherapy with 5-fluorouracil: a review. J Am Acad Dermatol. 1981;4(6):633–649.
- Ceglio WQGW, Rebeis MM, Santana MF, et al. Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital. An Bras Dermatol. 2022;97(1):14–21.
- Utlu Z, Bilen H. Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients. Postepy Dermatol Alergol. 2021;38(6):1078–1085.